Literature DB >> 16702592

A framework for management of hepatitis C in prisons.

Anne C Spaulding1, Cindy M Weinbaum, Daryl T-Y Lau, Richard Sterling, Leonard B Seeff, Harold S Margolis, Jay H Hoofnagle.   

Abstract

The prevalence of chronic hepatitis C virus (HCV) infection in prisons ranges from 12% to 31%. There are generally accepted--albeit still evolving--guidelines for identification and treatment of hepatitis C in the community. However, there is less agreement among health professionals caring for prisoners about best practices for identification, medical management, and treatment of hepatitis C. Inmates often lack health care before incarceration. In prisons, infected persons could be identified and the management of infection initiated; however, the high prevalence of HCV infection among prisoners would impose a disproportionate cost for hepatitis C care on the correctional system. The optimal solution is for prison and public health systems in the United States to jointly provide targeted HCV testing and standard-of-care hepatitis C medical management, treatment, and prevention programs to prison inmate populations. The authors report on a January 2003 meeting of experts in prison health, public health, hepatology, and infectious diseases and explore the clinical care, prevention, and collaboration needed to provide hepatitis C management in prisoners.

Entities:  

Mesh:

Year:  2006        PMID: 16702592     DOI: 10.7326/0003-4819-144-10-200605160-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Viral hepatitis in Hawai'i--differing perspectives.

Authors:  Alan D Tice; Michael Bannan; Kay Bauman; Tarquin Collis; Alba Hall; William Haning; Shoshana Hannemann; C Bradley Hare; Joseph Humphry; Robert Jao; Carroll Leevy; Heather Lusk; Edward Ochoa; Neal Palafox; Nancy Withers; Kenneth Akinaka
Journal:  Hawaii Med J       Date:  2010-04

3.  Hepatitis C among clients of health care for the homeless primary care clinics.

Authors:  Aaron J Strehlow; Marjorie J Robertson; Suzanne Zerger; Catherine Rongey; Lisa Arangua; Ed Farrell; Adele O'Sullivan; Lillian Gelberg
Journal:  J Health Care Poor Underserved       Date:  2012-05

4.  A "one-two punch" leading to hepatitis C seroconversion.

Authors:  Ellen H Nagami; Arthur Y Kim; Christopher E Birch; Melinda J Bowen; Barbara H McGovern
Journal:  Clin Infect Dis       Date:  2010-12-28       Impact factor: 9.079

5.  Liver cancer mortality among male prison inmates in Texas, 1992-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Karen J Goodman; Sandi L Pruitt
Journal:  Prev Med       Date:  2009-03-13       Impact factor: 4.018

6.  Hepatitis C viral infection in incarcerated patients.

Authors:  John Rice; Lisa Cervantes; Michael R Lucey
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-07-23

7.  Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.

Authors:  Aiden K Varan; Daniel W Mercer; Matthew S Stein; Anne C Spaulding
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

8.  Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C.

Authors:  Kara W Chew; Scott A Allen; Lynn E Taylor; Josiah D Rich; Edward Feller
Journal:  J Clin Gastroenterol       Date:  2009-08       Impact factor: 3.062

9.  HCV-related mortality among male prison inmates in Texas, 1994-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Michael F Kelley; Pamela M Diamond; Karen J Goodman; David P Paar
Journal:  Ann Epidemiol       Date:  2009-05-13       Impact factor: 3.797

10.  Testing for sexually transmitted infections and blood borne viruses on admission to Western Australian prisons.

Authors:  Rochelle E Watkins; Donna B Mak; Crystal Connelly
Journal:  BMC Public Health       Date:  2009-10-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.